Maybe it should be put out there that MSA is a type of Parkinson's. Although unlike the big Parkinson's market, which has some effective treatments, there is nothing for MSA Parkinson's. Nothing but a relentless progression to a nasty end. I recall the possible market size of around $1B. Current market cap of $21m. If the 201 trial is successful enough to predict an approvable drug, all the elements are there for this to go berserk at some stage.
Also this being a terminal disease, with not even an approved drug to slow progression, there could be pressure to bring this to market fast.
I believe early stage was chosen because it has a much better chance of success than the late stage results just revealed, which were ok imo.
DYOR
.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-123
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $5.491K | 1.520M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 50987030 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126437200 | 27 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |